Trial · NCT01425008
Results by group604
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 604
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | TEAEs | 4 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | TEAEs | 3 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | TEAEs | 3 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | TEAEs | 3 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | TEAEs | 7 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | TEAEs | 7 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | TEAEs | 3 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | TEAEs | 3 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | TEAEs | 13 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | TEAEs | 4 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | TEAEs | 16 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | TEAEs | 8 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | TEAEs | 16 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | TEAEs | 1 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | TEAEs | 6 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | TEAEs | 11 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | TEAEs | 20 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | TEAEs | 19 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | Q2D Dose Expansion Phase: TAK-580 (BRAF+) | TEAEs | 2 | Participants | |
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | SAEs | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01425008/results